Insulin retreats blamed for Generex stock drop

Generex is firmly in the camp that sees the glass as half full. After seeing its share price slide 16 percent yesterday, the developer attributed the sudden setback to decisions by Eli Lilly, Pfizer and Novo Nordisk to pull out of programs to develop other inhaled insulin products.

Worried? No, says Generex, happy to extol its late-stage drug's safety profile. The company says its Oral-lyn insulin doesn't leave a deposit in the lungs. And there's reason for cheer; the departure of the big companies removes some heavyweight competitors, says Generex.

Generex's stock woes followed a recent announcement from Alkermes that Eli Lilly is dropping out of their collaboration on an inhaled insulin therapy. Novo Nordisk and Pfizer have already pulled out of their respective programs. MannKind, meanwhile, reiterated its plans to forge ahead in the field.

- see the statement from Generex
- read the MarketWatch report

Related Articles:
Analyst gives bullish assessment of Generex program. Report
Generex initiates Phase II Trial in breast cancer patients. Report
MannKind bets the farm on inhaled insulin. Report
Pfizer kills off Exubera, hunts for deals. Report
Novo Nordisk shelves inhaled insulin, axes staffers. Report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.